← Leaderboards
Joseph Isaac Shapiro
University Of Toledo Health Sci Campus
$1,102,178
Attributed
$2,204,356
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $566.9K · FY2011–14$1M$750K$500K$250K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$2,204,356 · 1
By mechanism
R01$2,204,356 · 1
Top collaborators
- Zijian Xie4 shared
Most similar at University Of Toledo Health Sci Campus
Same institution · by research overlap
- Zijian Xie$8,165,281
- Amir Askari$3,435,700
- Edwin Ramon Sanchez$3,707,667
- Sandrine V Pierre$2,625,826
- Manohar Ratnam$6,528,945
Others in their field
Top investigators on “Abbreviations”
- Randall J Bateman · Washington University$53,745,733
- Muredach P Reilly · Columbia University Health Sciences$38,227,725
- Gary Steven Firestein · University Of California San Diego$35,352,070
- Jennifer A Pietenpol · Vanderbilt University$30,520,798
- Gerard David Schellenberg · University Of California San Diego$27,352,734
- Katherine F Luzuriaga · Univ Of Massachusetts Med Sch Worcester$25,574,475
Research focus
AbbreviationsAffinityAgonistAngiotensin IiAnimalsAntibodiesAttenuatedBaseBinding (Molecular Function)BiologyBlood PressureCardiacCardiac GlycosidesCardiomyopathiesCell Culture TechniquesCellsChronicChronic Kidney FailureComplexCongestive Heart FailureCultured CellsDietDominant-Negative Mutation1-Phosphatidylinositol 3-Kinase
Grant awards (4)
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac Diseases$535,678
R01 · FY2014 · HL
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac Diseases$537,347
R01 · FY2013 · HL
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac Diseases$564,441
R01 · FY2012 · HL
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac Diseases$566,890
R01 · FY2011 · HL